Cambridge University Hospitals group launches experimental drug trial to treat Covid-19
Cambridge University Hospitals group is launching a fast-turnaround experimental drug trial to treat Covid-19.
Two new treatments which tackle aspects of the coronavirus infection are to be tested in the innovative trial which will respond quickly to results from small numbers of patients.
The newly launched trial, known as TACTIC-E (the “E” stands for “experimental”), has been designed to test drugs that have been specifically developed to treat Covid-19 as well as investigating whether combinations of drugs that are already in use can be effective.
The trial will determine whether the major organ complications in severe Covid-19 can be reduced (or prevented) by targeting previously unexplored pathways, via the gut, to reduce the inflammatory response, and via the inner lining of blood vessels, to help increase the amount of oxygen available in the lungs.
One of the drugs to be used in the trial is called EDP1815. The other arm of the trial will involve using two drugs in combination: Dapagliflozin and Ambrisentan.
For more information visit: ITV News
Published May 22, 2020
Latest from CCTU
Improving outcomes for Crohn's patients
Treating newly-diagnosed patients with advanced therapy leads to dramatic improvements in outcomes.
Roll out of Cambridge-developed artificial pancreas is world first
An artificial pancreas developed with the help of staff and patients at Addenbrooke's Hospital is one of four new devices to be rolled out by…
New clues about irritable bowel syndrome found in the brain
Breakthrough research led by Addenbrooke's Hospital gives IBS patients like Laura Tebbs a better understanding of their condition.
